IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Pier Paolo PiccalugaDavide Gibellini

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical course is typically indolent; however, based on a series of pathobiological, clinical, genetic, and phenotypic parameters, patient survival varies from less than 5 to more than 20 years. In this paper, we show for the first time that the expression of the interferon-inducible DNA sensor IFI16, a member of the PYHIN protein family involved in proliferation inhibition and apoptosis regulation, is associated with the clinical outcome in CLL. We studied 99 CLLs cases by immunohistochemistry and 10 CLLs cases by gene expression profiling. We found quite variable degrees of IFI16 expression among CLLs cases. Noteworthy, we observed that a reduced IFI16 expression was associated with a very poor survival, but only in cases with ZAP70/CD38 expression. Furthermore, we found that IFI16 expression was associated with a specific gene expression signature. As IFI16 can be easily detected by immunohistochemistry or flow cytometry, it may become a part of phenotypic screening in CLL patients if its prognostic role is confirmed in independent series.

References

Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Jan 28, 2003·Histochemistry and Cell Biology·Wu WeiRicky W Johnstone
Aug 20, 2003·The Journal of Biological Chemistry·Jennifer C KwakSam W Lee
Mar 3, 2004·The Journal of Biological Chemistry·Nobuko FujiuchiToru Ouchi
May 18, 2005·Experimental Cell Research·Louise E A LudlowChristopher J P Clarke
Oct 28, 2005·The New England Journal of Medicine·George Adrian CalinCarlo M Croce
Feb 17, 2007·The Journal of Clinical Investigation·Pier Paolo PiccalugaStefano A Pileri
Jun 16, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Yan ZhangChuan-ju Liu
Nov 6, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Divaker ChoubeyShuk-mei Ho
Nov 1, 2008·Molecular Cancer Research : MCR·Lynda Li SongDivaker Choubey
Oct 5, 2010·Nature Immunology·Leonie UnterholznerAndrew G Bowie
Jan 5, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Marisa GariglioSanto Landolfo
Jan 27, 2011·Nature Reviews. Immunology·Søren R PaludanKatherine A Fitzgerald
Apr 9, 2013·Hematology/oncology Clinics of North America·Peter Dreger, UNKNOWN European Group for Blood and Marrow Transplantation (EBMT)
May 2, 2013·Haematologica·Robin FoàGianluca Gaidano
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pietro BulianValter Gattei
Jul 23, 2014·Seminars in Hematology·Michele Dal BoValter Gattei
Dec 3, 2014·JAMA : the Journal of the American Medical Association·Chadi Nabhan, Steven T Rosen
Feb 7, 2015·Cancer Treatment and Research·Clare Sun, Adrian Wiestner
Jul 18, 2015·Journal of Immunology Research·Pier Paolo PiccalugaDavide Gibellini

❮ Previous
Next ❯

Citations

May 10, 2020·Journal of Integrative Bioinformatics·Vânia Rodrigues, Sérgio Deusdado
Jan 27, 2019·Nature Reviews. Drug Discovery·Ernest C Borden
Jan 25, 2020·American Journal of Clinical Pathology·Hao LiZhi-Jun Sun
Mar 14, 2021·The Pharmacogenomics Journal·Wenhui HuangCong Deng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.